Search

Your search keyword '"Nakagawa, Taku"' showing total 394 results

Search Constraints

Start Over You searched for: Author "Nakagawa, Taku" Remove constraint Author: "Nakagawa, Taku"
394 results on '"Nakagawa, Taku"'

Search Results

1. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)

4. Core-Mantle Co-Evolution: An Interdisciplinary Approach

5. Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)

6. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

7. Development of a rapid detection method for the macrolide resistance gene in Mycobacterium avium using the amplification refractory mutation system–loop-mediated isothermal amplification method

10. Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)

11. Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)

15. Clinico-microbiological analysis of 121 patients with pulmonary Mycobacteroides abscessus complex disease in Japan – An NTM-JRC study with RIT

16. Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).

17. A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety

21. Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

22. Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

23. Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

24. Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

25. Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

29. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)

32. MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study

33. Successful Treatment of Transplantation-associated Atypical Hemolytic Uremic Syndrome With Eculizumab

34. Real-World Outcomes of Chemotherapy for Lung Cancer Patients Undergoing Hemodialysis: A Multicenter Retrospective Cohort Study (NEJ-042)

36. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

43. Molecular typing of Mycobacterium intracellulare using multilocus variable-number of tandem-repeat analysis: identification of loci and analysis of clinical isolates

Catalog

Books, media, physical & digital resources